Psomagen, Inc. (KOSDAQ:950200)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,640.00
-135.00 (-3.58%)
At close: Apr 28, 2026
5.81%
Market Cap 71.85B
Revenue (ttm) 59.19B
Net Income (ttm) -2.98B
Shares Out 19.24M
EPS (ttm) -156.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 106,005
Average Volume 168,485
Open 3,790.00
Previous Close 3,775.00
Day's Range 3,605.00 - 3,790.00
52-Week Range 3,145.00 - 4,665.00
Beta -0.20
RSI 55.33
Earnings Date Mar 27, 2026

About Psomagen

Psomagen, Inc. engages in the provision omics solutions and contract laboratory services. The company’s research services includes genomics, a study of gene sequence and expression; epigenomics, a study of epigenetic changes, such as chromatin assembly, histone modification, and DNA-protein interaction in a cell; single-cell analysis, research in suspensions, biological fluids, tissues, or cell populations; metagenomics, a study of genetic material from microorganisms in heterogeneous samples; transcriptomics, a study of RNA and its expression ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2004
Employees 85
Stock Exchange KOSDAQ
Ticker Symbol 950200
Full Company Profile

Financial Performance

In 2025, Psomagen's revenue was 59.19 billion, an increase of 35.56% compared to the previous year's 43.66 billion. Losses were -2.98 billion, -46.90% less than in 2024.

Financial Statements

News

There is no news available yet.